JAM
TGTX icon

Jupiter Asset Management’s TG Therapeutics TGTX Stock Holding History

Jupiter Asset Management’s Portfolio TGTX Stock Details TGTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-46,577
Closed -$708K – 460
2024
Q1 		$708K Sell
46,577
-108,260
-70% -$1.72M 0.01% 384
2023
Q4 		$2.64M Buy
+154,837
New +$1.8M 0.03% 306

Other funds holding TGTX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $94.8B AUM 24.11% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Jupiter Asset Management's TGTX Position: Q2 2024 in Review

Jupiter Asset Management sold out of TG Therapeutics (TGTX) in Q2 2024, closing a stake of 46,577 shares — an estimated $708K sold.

Jupiter Asset Management first reported a position in TGTX in Q4 2023 and held it in 2 quarters. The position peaked at $2.64M in Q4 2023. 259 funds tracked by Wall St. Rank hold TGTX as of Q2 2024.

  • Jupiter Asset Management reported no remaining TG Therapeutics position as of Q2 2024 after selling out during the quarter.
  • Jupiter Asset Management sold 46,577 TG Therapeutics shares in Q2 2024, an estimated $708K.
  • Jupiter Asset Management first reported a position in TG Therapeutics in Q4 2023 and held it in 2 quarters.
  • Jupiter Asset Management's TG Therapeutics position peaked at $2.64M in Q4 2023.
  • 259 funds tracked by Wall St. Rank held TG Therapeutics as of Q2 2024.

Based on Jupiter Asset Management's 13F filing for Q2 2024, filed 8 Aug 2024.